ClinicalTrials.gg
CompletedNCT01850160Updated Jan 26, 2016

Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension

A Phase 3 interventional study of GROUP A: Valsartan plus Chlorthalidone and GROUP B: Valsartan in Hypertension, sponsored by Farma de Colombia SA. Completed at 8 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-01-26.

Sponsored by Farma de Colombia SA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
85th of 139
124 · median 198
Started
2013
with 2 others
Phase 3
53 of 140
none open now
Registered
121st of 140
by date

Among the 140 studies testing valsartan in Hypertension, this one is the 85th largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2013, is one of 53 in phase 3, and was the 121st registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

This trial is aimed to assess the efficacy and safety of a fixed-dose combination therapy with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone alone for treatment of adult patients with diagnosis of arterial hypertension.

Read the detailed description

In spite of the existence of a great variety of treatments with drugs effective against arterial hypertension, the percentages of arterial hypertension control with monotherapy remain quite low reason why the fixed-dose combinations of drugs have been one of the most interesting research topics in order to achieve an appropriate control of arterial hypertension.

The possibility of achieving better coverage and Blood Pressure control through a drug combination has leaded, on a scientific base of the efficacy of an Angiotensin Receptor Blockers II plus diuretic combination, to the development of a great number of combinations with different Angiotensin II Receptor Blockers plus hydrochlorothiazide. Yet it is noteworthy that despite the increasing evidence showing additional benefits in Blood pressure control and reduction of cardiovascular outcomes with chlorthalidone over hydrochlorothiazide, there is neither a great number of combinations nor studies with Angiotensin II Receptor Blockers plus chlorthalidone whereby the conduction of a trial assessing the efficacy and safety of Valsartan plus chlorthalidone in hypertensive patients is proposed plus the benefits of combination therapy that include, among others, the greater efficacy with lower doses of each individual component as well as reduction in occurrence of adverse events directly related with lower drug doses.With this treatment schedule it is expected to obtain higher control of blood pressure values and greater percentage of patients.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • High blood pressure
  • Drug therapy combination
  • Valsartan
  • Chlorthalidone
  • Safety
  • Efficacy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with diagnosis of arterial hypertension defined as:
  • Systolic blood pressure greater or equal to 140 and lower than 180 mmHg
  • Diastolic blood pressure greater or equal to 90 and lower than 110 mmHg
  • Non controlled patients with antihypertensive treatment (blood pressure values: Systolic blood pressure > 140 mmHg and/or Diastolic blood pressure > 90 mmHg) or patients antihypertensive treatment-naïve.
  • Likelihood of attending consultations according to the trial chronogram.
  • Signature.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of severe or malignant arterial hypertension defined as:
  • Systolic blood pressure greater or equal to 180 mmHg
  • Diastolic blood pressure greater or equal to 110 mmHg
  • Patients with secondary arterial hypertension of any etiology.
  • Pregnant women or women with who are not using appropriate methods; women planning to become pregnant during the trial.
  • Patients with history of Acute Myocardial Infarction o Angina Pectoris within the 6 months prior to the trial initiation.
  • Diagnosis of Cerebrovascular Disease (CVD) o (TIA) within the 6 previous months.
  • Patients with Severe Renal Disease defined by serum Creatinine levels higher than 1.5 mg/dl.
  • Diagnosed or suspected unilateral or bilateral renal artery stenosis.
  • History of non remitting cancer within the 5 years prior to the trial initiation.
  • Patients with Hypokalemia or Hyperkalemia.
  • Patients receiving Valsartan or Chlortalidone during the 14 previous days.
  • Patients with known to Valsartan or Chlorthalidone.
  • Unstable patients with antecedent of hospitalization within the 4 days prior to their enrollment in the trial.
  • Patients with history of drugs and alcohol abuse within the last year.
  • Patients who have taken part in other clinical trial within the 4 weeks prior to the initiation of this research.
  • Patients with any other clinical condition that the investigator deems may affect the patient follow-up.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    GROUP A: Valsartan plus Chlorthalidone

    GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.

    Drug: GROUP A: Valsartan plus Chlorthalidone

  • Experimental
    GROUP B: Valsartan

    GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.

    Drug: GROUP B: Valsartan

  • Experimental
    GROUP C: Chlorthalidone

    GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.

    Drug: GROUP C: Chlorthalidone

Interventions

  • DrugGROUP A: Valsartan plus Chlorthalidone

    Drug pages: Valsartan · Chlorthalidone

    Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.

    Also known as: Chlorthalidone Drug Combination, Valsartan Drug Combination, Antihypertensive Agents

  • GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.

    Also known as: Angiotensin II Receptor Antagonist, Antihypertensive Agents

  • GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.

    Also known as: Sodium Chloride Symporter Inhibitors, Antihypertensive Agents, Diuretics

06

What researchers measure

Primary outcomes

  1. Safety and Efficacy of the fixed-dose combination treatment with Valsartan plus Chlorthalidone

    Efficacy and safety of a fixed-dose combination treatment of Valsartan plus Chlorthalidone Vs Valsartan or Chlorthalidone alone in the treatment of patients with arterial hypertension

    Time frame: 12 weeks

Secondary outcomes

  1. Changes in Systolic and Diastolic Blood pressure values

    Assess the changes in Systolic and Diastolic Blood Pressure from baseline up to week 12

    Time frame: 12 weeks

  2. Changes of Systolic blood pressure values

    Assess the changes of systolic blood pressure from baseline up to week 6 and 12

    Time frame: 12 weeks

  3. Changes of Diastolic blood pressure values

    Assess the changes of diastolic blood pressure from baseline up to week 6 and 12

    Time frame: 12 weeks

  4. Changes of diastolic blood pressure in arterial blood pressure median values

    Assess the changes in diastolic blood pressure in Arterial Blood Pressure Media from baseline up to week 12

    Time frame: 12 weeks

  5. Changes of systolic blood pressure values in arterial blood pressure median values

    Assess the change in systolic blood pressure in Arterial Blood Pressure Median from baseline up to week 12

    Time frame: 12 weeks

  6. Patient that achieving blood pressure values lower than 140/90 (systolic/diastolic) at week 6 and 12

    Determine the percentage of patients achieving blood pressure values lower than 140/90 (systolic/diastolic) at weeks 6 and 12

    Time frame: 12 weeks

  7. Patients that achieving systolic blood pressure values lower than 140 at week 6 and 12

    Determine the percentage of patients achieving systolic blood pressure lower than 140 at weeks 6 and 12

    Time frame: 12 weeks

  8. Patients that achieving diastolic blood pressure values lower than 90 at week 6 and 12

    Determine the percentage of patients achieving diastolic blood pressure lower than 90 at week 6 and 12

    Time frame: 12 weeks

Other outcomes

  1. Metabolic changes secondary to the treatment with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone

    Identify if there are significant differences regarding metabolic changes secondary to the treatment with Valsartan and Chlorthalidone Vs Valsartan or Chlorthalidone.

    Time frame: 12 weeks

  2. Incidence of adverse events in each intervention group

    Determine the percentage of incidence of adverse events in each intervention group.

    Time frame: 12 weeks

07

Study locations

8 sites
  • Centro de Diagnostico Cardiologico
    Cartagena, Bolivar 130001, Colombia
  • Fundacion Cardiomet Cequin
    Armenia, Quindio 630001, Colombia
  • MedPlus
    Bogota DC, 11001, Colombia
  • Centro AMCOR
    Quito, EC170150, Ecuador
  • Centro Clinico quirurgico
    Quito, EC170150, Ecuador
  • Centro médico de hipertensión arterial
    Quito, EC170150, Ecuador
  • Clínica DAME
    Quito, EC170150, Ecuador
  • Consultorio Edificio Novoa
    Quito, EC170150, Ecuador
08

References and documents

Publications

  • Manzur F, Rico A, Romero JD, Rodriguez-Martinez CE. Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patients With Mild to Moderate Hypertension: The VACLOR Study. Clin Med Insights Cardiol. 2018 Sep 3;12:1179546818796482. doi: 10.1177/1179546818796482. eCollection 2018. PubMed 30202211 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Mar 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2013
First posted
May 9, 2013
Start
Apr 2013
Primary completionActual
Mar 2015
CompletionActual
May 2015
Last update
Jan 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01850160
Lead sponsor
Farma de Colombia SA
Responsible party
Sponsor
First posted
May 9, 2013
Start date
Apr 2013
Primary completion
Mar 2015
Completion
May 2015
Last update
Jan 26, 2016

Study contacts

Juan D Romero, MD
study director · Farma de Colombia SA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Chlorthalidone

Start the discussion